Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer | Zendy

Jeffrey J. Tosoian | Zendy; Stacy Loeb | Zendy; Zhaoyong Feng | Zendy; Sumit Isharwal | Zendy; Patricia Landis | Zendy; Debra J. Elliot | Zendy; Robert W. Veltri | Zendy; Jonathan I. Epstein | Zendy; Alan W. Partin | Zendy; H. Ballentine Carter | Zendy; Bruce J. Trock | Zendy; Lori J. Sokoll | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

Author(s) -

Jeffrey J. Tosoian,

Stacy Loeb,

Zhaoyong Feng,

Sumit Isharwal,

Patricia Landis,

Debra J. Elliot,

Robert W. Veltri,

Jonathan I. Epstein,

Alan W. Partin,

H. Ballentine Carter,

Bruce J. Trock,

Lori J. Sokoll

Publication year - 2012

Publication title -

the journal of urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.402

H-Index - 256

eISSN - 1527-3792

pISSN - 0022-5347

DOI - 10.1016/j.juro.2012.06.009

Subject(s) - medicine , prostate cancer , biopsy , prostate specific antigen , prostate , prostate biopsy , cancer , proportional hazards model , watchful waiting , urology , oncology

Previous studies have suggested an association between [-2]proPSA expression and prostate cancer detection. Less is known about the usefulness of this marker in following patients with prostate cancer on active surveillance. Thus, we examined the relationship between [-2]proPSA and biopsy results in men enrolled in an active surveillance program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research